Today: William H. Rastetter Buys 375,939 Shares of Fate Therapeutics Inc. (FATE) Stock

Today: William H. Rastetter Buys 375,939 Shares of Fate Therapeutics Inc. (FATE) Stock

Fate Therapeutics Inc. (NASDAQ:FATE) Director William H. Rastetter purchased 375,939 shares of the company’s stock in a transaction on Wednesday, November 23rd. The stock was acquired at an average price of $2.66 per share, for a total transaction of $999,997.74. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Fate Therapeutics Inc. (NASDAQ:FATE) traded down 2.83% during trading on Monday, reaching $3.09. The company’s stock had a trading volume of 310,834 shares. The firm’s market cap is $105.52 million. Fate Therapeutics Inc. has a 52 week low of $1.46 and a 52 week high of $4.67. The stock’s 50 day moving average is $2.50 and its 200-day moving average is $2.26.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.02. Fate Therapeutics had a negative return on equity of 112.48% and a negative net margin of 740.69%. On average, equities research analysts forecast that Fate Therapeutics Inc. will post ($1.14) earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of FATE. Northern Trust Corp raised its position in shares of Fate Therapeutics by 51.3% in the third quarter. Northern Trust Corp now owns 38,625 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 13,094 shares during the period. Redmile Group LLC raised its position in shares of Fate Therapeutics by 1.0% in the second quarter. Redmile Group LLC now owns 1,502,180 shares of the biopharmaceutical company’s stock valued at $2,554,000 after buying an additional 15,200 shares during the period. Lombard Odier Asset Management USA Corp raised its position in shares of Fate Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 256,426 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 7,052 shares during the period. Board of Trustees of The Leland Stanford Junior University purchased a new position in shares of Fate Therapeutics during the second quarter valued at about $495,000. Finally, BlackRock Fund Advisors raised its position in shares of Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares during the period. 57.07% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have commented on FATE shares. Roth Capital started coverage on shares of Fate Therapeutics in a research report on Thursday, September 22nd. They issued a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Thursday, August 11th. HC Wainwright reissued a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, August 9th. BMO Capital Markets set a $4.00 price target on Fate Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 8th. Finally, Wedbush dropped their price target on Fate Therapeutics from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $5.79.

Fate Therapeutics Company Profile

Related posts

Leave a Comment